ORIGINAL RESEARCH article

Front. Oncol.

Sec. Gastrointestinal Cancers: Colorectal Cancer

Volume 15 - 2025 | doi: 10.3389/fonc.2025.1562634

This article is part of the Research TopicCancer and Viral Immunotherapeutic Approaches: From Computers to Experimental ScienceView all articles

Factors Affecting Survival Prognosis of Patients with Rectal Cancer After Neoadjuvant Chemoradiotherapy Author and unit information

Provisionally accepted
Baokun  LiBaokun Li1Jiachao  HanJiachao Han1Feifei  WangFeifei Wang1Bin  YuBin Yu1Guiying  WangGuiying Wang1Fei  YangFei Yang2*
  • 1Second Department of Surgery, Fourth Hospital, Hebei Medical University, Shijiazhuang, Hebei Province, China
  • 2Department of Otolaryngology Head and Neck Surgery, Fourth Hospital of Hebei Medical University, Hebei, China

The final, formatted version of the article will be published soon.

Objective: To identify potential factors influencing the survival prognosis of locally advanced rectal cancer patients receiving neoadjuvant chemoradiotherapy.: A retrospective study was conducted to collect data from January 2009 to December 2020 on 270 patients with locally advanced rectal cancer who were admitted to the Fourth Hospital of Hebei Medical University. The clinical data of patients before and after neoadjuvant chemoradiotherapy and postoperative treatment were compiled.. The endpoints of the study were disease-free survival and overall survival of the patients. The univariate and multivariable regression analysis were used to identify factors that influence the patients' survival prognosis. Results: Univariate analysis showed that factors associated with good prognosis in neoadjuvant chemotherapy patients included age <65 years, CEA value ≤5ng/mL, lymphocyte count >1.5×10 9 /L, normal albumin level, NLR ≤2.64, SII ≤683.16, PNI >49.23, tumor distance from the anal margin >5cm, tumor length ≤5cm, tumor invasion of the bowel wall ratio ≤50%, lower T stage and N stage, good tumor regression response, absence of KRAS gene mutation, and mismatch repair protein deficiency. And multivariate analysis showed that age (HR=0.385, P=0.007), NLR (HR=0.294, P=0.011), cT stage (HR=0.287, P<0.001), and tumor regression grade (HR=0.273, P<0.001) were significant factors influencing DFS in patients receiving neoadjuvant chemoradiotherapy. For OS, age (HR=0.497, P=0.035), cT stage (HR=0.387, P=0.001), and tumor regression grade (HR=0.307, P<0.001) were significant factors influencing OS in patients receiving neoadjuvant chemoradiotherapy. Conclusion: Age, cT stage, NLR, and tumor regression grade are significant factors influencing DFS and OS in patients with locally advanced rectal cancer. Younger age, lower cT stage, lower NLR value, and lower tumor regression grade are associated with better survival prognosis.

Keywords: rectal cancer, Locally advanced stage, Neoadjuvant Therapy, Pathological complete response, prognosis

Received: 17 Jan 2025; Accepted: 16 Apr 2025.

Copyright: © 2025 Li, Han, Wang, Yu, Wang and Yang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Fei Yang, Department of Otolaryngology Head and Neck Surgery, Fourth Hospital of Hebei Medical University, Hebei, China

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Research integrity at Frontiers

94% of researchers rate our articles as excellent or good

Learn more about the work of our research integrity team to safeguard the quality of each article we publish.


Find out more